Explore Stanford technologies available for licensing:

Cell culture is a central technique used for a plethora of research applications including in the modeling of complex diseases, creating transgenic animals, gene therapy, cell therapy, regenerating lost tissue, and organ biogenesis.

Stanford researchers have developed novel viral markers from tomato brown rugose fruit virus (ToBRFV). The marker is a good indicator of 1) environmental fecal contamination, 2) fecal load in wastewater, and 3) internal control for viral RNA extraction from stool.

Stanford researchers in the Khosla lab have invented a new class of "molecular glues" that couple the enzymatic activity of a cell-surface enzyme, transglutaminase 2 (TG2), with the ability of the LDL receptor-related protein 1 (LRP-1) to promote receptor-mediated endocytosis

Researchers at Stanford have developed a new methodology for image processing that allows for high-throughput characterization of organoid phenotypes.

Researchers at Stanford have developed a multiplexed bead-based dephosphorylation assay to allow for the measurement of multiple dephosphorylation reactions in one experiment.

Stanford researchers in the Wu Lab have developed hypoallergenic and immunogenic induced pluripotent stem cells that could be used as a cancer treatment or prophylactic.

Researchers at Stanford have developed a potent, insulin-based, insulin receptor antagonist that could be used as a hyperinsulinism therapeutic.

Stanford researchers have developed a single-cell technology for a targeted high-throughput multiomic readout of RNA and gDNA.

Technology Reference
CZ Biohub SF ref. no. CZB-231S
Stanford ref. no. S21-400

Researchers at Stanford have developed a new microparticle vaccine scaffold for the development of immunogenic subunit vaccines.

Stanford inventors have developed an early-stage screening method to diagnose abdominal aortic aneurysms (AAA). AAA is a common cardiovascular disease with high prevalence in European men 65 years and above.

Background

Technology Reference
CZ Biohub ref. no. CZB-208S
Stanford ref. no. S21-125

Researchers at Stanford have developed a method to identify cell types of origin for cell-free RNA from liquid biopsies for a variety of diseases.

Technology Reference
CZB-213S
Stanford ref. no. S21-152

Researchers at CZ Biohub SF and Stanford have developed unique fusion proteins that have broad therapeutic benefits for the treatment of infection by existing and future coronaviruses.

Technology Reference
CZ Biohub ref. no. CZB-221S
Stanford ref. no. S21-272

Researchers at Stanford have developed a new therapeutic avenue for the treatment of RNA viral infections.

Immune checkpoint blockade, a class of immunotherapy treatment which works by blocking inhibitory receptors on T cells to improve immune responses, has proven to be a remarkable clinical advance in the treatment of many diseases, particularly in cancer.